{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:56Z","timestamp":1785387596006,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hydroxocobalamin (OHCbl), the most effective form of vitamin B12 containing cobalt (Co) as its core component, is the mainstay therapy for cobalamin C (cblC) defect, yet long-term Co exposure and safety signals remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 379 cblC patients receiving OHCbl therapy. Among them, 270 had prognostic data and 99 had laboratory and Co measurements. Adverse drug reactions (ADRs) were evaluated using the Naranjo scale. Regression models identified determinants of Co levels and associations of OHCbl dosage, treatment duration, and Co concentration with routine laboratory parameters, potential ADRs and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median treatment duration was 76.70 months and median OHCbl dosage was 1.07 mg\/kg\/week; Median blood Co concentration was 22.53 \u03bcg\/L. Although 53.54% of patients having Co &amp;gt;20.00 \u03bcg\/L, no severe Co toxicity was observed. OHCbl dosage was the only independent predictor of Co (\u03b2 = 0.70,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). In adjusted analyses of 29 routine laboratory indicators, no association with OHCbl dosage, treatment duration, or blood Co remained significant after Benjamini\u2013Hochberg false discovery rate correction (all\n                      <jats:italic>q<\/jats:italic>\n                      &amp;gt; 0.05). ADRs occurred in 82.6% of patients, most commonly chromaturia (80.39%), psychomotor agitation (8.84%), and localized rash (5.52%), and were predominantly mild and self-limited. Higher OHCbl dosage was associated with increased odds of any potential ADR (OR = 3.61) and chromaturia (OR = 3.00); longer treatment duration was independently associated with better overall prognosis (OR = 1.02), and no associations with injury to specific organ systems were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OHCbl remains well tolerated even with prolonged, higher-dosage treatment, supporting its continued long-term use with routine monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1843743","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:47Z","timestamp":1785385307000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of blood cobalt levels and safety of long-term hydroxocobalamin therapy in patients with cblC defect"],"prefix":"10.3389","volume":"13","author":[{"given":"Lili","family":"Hao","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijuan","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichuang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianshu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jimd.12370","article-title":"Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision","volume":"44","author":"Forny","year":"2021","journal-title":"J Inherit Metab Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/09691413211021621","article-title":"Newborn screening for inherited metabolic diseases using tandem mass spectrometry in China: outcome and cost-utility analysis","volume":"29","author":"Zhao","year":"2022","journal-title":"J Med Screen."},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5582\/irdr.2018.01026","article-title":"Methylmalonic acidemia: current status and research priorities","volume":"7","author":"Zhou","year":"2018","journal-title":"Intractable Rare Dis Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13023-024-03021-3","article-title":"Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): systematic review","volume":"19","author":"Arhip","year":"2024","journal-title":"Orphanet J Rare Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"109182","DOI":"10.1016\/j.ymgme.2025.109182","article-title":"et al. Variable phenotypes and outcomes associated with the MMACHC c1A>G variant in Chinese patients with combined methylmalonic acidemia and homocystinuria cblC type","volume":"145","author":"Hao","year":"2025","journal-title":"Mol Genet Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1038\/s41390-024-03581-x","article-title":"Long-term follow-up of Chinese patients with methylmalonic acidemia of the cblC and mut subtypes","volume":"97","author":"Hao","year":"2025","journal-title":"Pediatr Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"104981","DOI":"10.1016\/j.isci.2022.104981","article-title":"Dereven'kov IA, Makarov SV, Jacobsen DW, Spiekerkoetter U, et al","volume":"25","author":"Esser","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12519-023-00770-2","article-title":"E HS, Yu Y, Ling SY, Liang LL, Qiu WJ, et al. Variable phenotypes and outcomes associated with the MMACHC c482G > A mutation: follow-up in a large CblC disease cohort","volume":"20","author":"Wu","year":"2024","journal-title":"World J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3724\/zdxbyxb-2021-0276","article-title":"et al. Clinical features and outcomes of patients with cblC type methylmalonic acidemia carrying gene c609G>A mutation","volume":"50","author":"Yu","year":"2021","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"B10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13023-023-02890-4","article-title":"Late-onset cblC defect: clinical, biochemical and molecular analysis","volume":"18","author":"Ding","year":"2023","journal-title":"Orphanet J Rare Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10545-016-9991-4","article-title":"Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency","volume":"40","author":"Huemer","year":"2017","journal-title":"J Inherit Metab Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"107681","DOI":"10.1016\/j.ymgme.2023.107681","article-title":"Would, early, versus late hydroxocobalamin dose intensification treatment, prevent cognitive decline, macular degeneration and ocular disease, in 5 patients with early-onset cblC deficiency?","volume":"140","author":"Scalais","year":"2023","journal-title":"Mol Genet Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e12787","DOI":"10.1002\/jimd.12787","article-title":"Improved biochemical and neurodevelopmental profiles with high-dose hydroxocobalamin therapy in cobalamin C defect","volume":"48","author":"Olivieri","year":"2025","journal-title":"J Inherit Metab Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/jbcr\/iraa024.139","article-title":"Outcomes after the administration of hydroxocobalamin","volume":"10","author":"Pruskowski","year":"2020","journal-title":"Int J Burns Trauma."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.burns.2024.04.007","article-title":"Hydroxocobalamin is not associated with methemoglobinemia in patients with inhalation injury and suspected cyanide toxicity and a proposed algorithm for hydroxocobalamin administration","volume":"50","author":"Stanton","year":"2024","journal-title":"Burns."},{"key":"B16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/BF01720716","article-title":"Hydroxocobalamin vs cobalt toxicity on rat cardiac and diaphragmatic muscles","volume":"22","author":"Pery-Man","year":"1996","journal-title":"Intensive Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15563650600811755","article-title":"Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study","volume":"1","author":"Uhl","year":"2006","journal-title":"Clin Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/00039896.1988.10545953","article-title":"Blood and urinary concentrations as estimators of cobalt exposure","volume":"43","author":"Alexandersson","year":"1988","journal-title":"Arch Environ Health."},{"key":"B19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/clinchem\/34.3.474","article-title":"Trace elements in human clinical specimens: evaluation of literature data to identify reference values","volume":"34","author":"Iyengar","year":"1988","journal-title":"Clin Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tox.2017.05.015","article-title":"Cobalt toxicity in humans-a review of the potential sources and systemic health effects","volume":"387","author":"Leyssens","year":"2017","journal-title":"Toxicology."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.98B1.36712","article-title":"Systemic cobalt toxicity from total hip arthroplasties: review of a rare condition Part 2. measurement, risk factors, and step-wise approach to treatment","author":"Zywiel","year":"2016","journal-title":"Bone Joint J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/jcla.21745","article-title":"Spectrum analysis of common inherited metabolic diseases in Chinese patients screened and diagnosed by tandem mass spectrometry","volume":"29","author":"Han","year":"2015","journal-title":"J Clin Lab Anal."},{"key":"B23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1289\/isee.2011.00684","volume":"45","author":"Zhu","year":"2011","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi."},{"key":"B24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/bcp.15704","article-title":"Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: a retrospective cohort study","volume":"89","author":"Um","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ymgme.2013.05.007","article-title":"Clinical and biochemical outcome after hydroxocobalamin dose escalation in a series of patients with cobalamin C deficiency","volume":"109","author":"Matos","year":"2013","journal-title":"Mol Genet Metab."},{"key":"B27","article-title":"Renal Function Tests","author":"Gounden","year":"2025"},{"key":"B28","article-title":"Hypergammaglobulinemia (Polyclonal Gammopathy)","author":"Rasel","year":"2025"},{"key":"B29","article-title":"Leukocytosis","author":"Mank","year":"2025"},{"key":"B30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s13023-025-03991-y","article-title":"Analysis of hydroxocobalamin dosage in patients with CblC deficiency","volume":"20","author":"Ding","year":"2025","journal-title":"Orphanet J Rare Dis."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1843743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:48Z","timestamp":1785385308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1843743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":30,"alternative-id":["10.3389\/fnut.2026.1843743"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1843743","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1843743"}}